CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.
GlobeNewsWire9/2/2026Neutral
CDT
Conduit Pharmaceuticals Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.56M
P/E Ratio
—
EPS
$-3050.69
Beta
1.45
52W High
$236.00
52W Low
$0.30
50-Day MA
$3.18
200-Day MA
$142.39
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage biopharmaceutical company focused on creating innovative therapies for oncology and rare diseases, targeting significant unmet medical needs. Utilizing its proprietary drug delivery technology, Conduit aims to improve the efficacy and safety of existing treatments, thereby enhancing patient outcomes and reducing adverse effects. Supported by a seasoned management team and strategic collaborations, the company is well-positioned to advance its pipeline of transformative products, with the potential to significantly influence the healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-22.83M |
| Operating Margin | 0.00% |
| Return on Equity | -69.70% |
| Return on Assets | -23.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $163.36 |
| Price-to-Book | 0.10 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -55.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.69M |
| Float | 712,810 |
| % Insiders | 51.93% |
| % Institutions | 0.12% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Latest News
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.
GlobeNewsWire9/1/2026Neutral
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds.
GlobeNewsWire8/28/2026Neutral
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a SAFE note with Pep'd Inc. (“Pep'd”), a US-based peptide company, expanding CDT's exposure to the growing US peptide market (the “Transaction”).
GlobeNewsWire8/25/2026Neutral
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that it has entered into a strategic transaction to increase its equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors, to 22.7% through the issuance of pre-funded warrants to purchase up to 12,131,770 shares of the Company's common stock, subject to shareholder approval at the Company's annual meeting of stockholders on August 28, 2026 (the “Transaction”).
GlobeNewsWire8/3/2026Neutral
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new patent application covering a large set of field-deployable, two-component combination interventions for sugarcane cultivation, generated through Sarborg's quantum-enabled PRISM platform.
GlobeNewsWire7/20/2026Neutral
CDT Equity Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-10 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule.
GlobeNewsWire7/16/2026Neutral
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its Signature Intelligence platform into quantum-assisted coformer selection through SarborgQ, the Company's dedicated quantum computing division.
GlobeNewsWire6/26/2026Neutral
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding its recent fundraise from a New York-based private investment fund.
GlobeNewsWire6/18/2026Neutral
CDT Equity Announces Debt Update and New Loan Facility
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has re-structured its debt, agreeing to pay off all outstanding amounts due under its Loan Notes with Alliance Global Partners (“A.G.P.
GlobeNewsWire6/16/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDT and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026